

Shuwen Biotech gets PD-L1 Detection Kit validation in Clinical Trials

17 September 2018 | News

Patients with advanced esophageal squamous cell carcinoma with higher PD-L1 expression can benefit better from leading PD-1 antibody drugs



Shuwen Biotech is the first in China to launch a locally manufactured proprietary PD-L1 test kit, which can accurately determine the expression status of PD-L1 in tumor tissues, and to provide laboratory testing services for anti-PD-L1/PD-1 drug development.

Recently, the investigation of the safety, efficacy and molecular marker efficacy of Hengrui Medicine's anti-PD-1 drug, SHR1210, in the treatment of patients with advanced esophageal squamous cell carcinoma who failed conventional therapy was published in the March 2018 issue of Clinical Cancer Research, in which one of Shuwen Biotech's PD-L1 detection kits was used and clinical results showed that patients positive for PD-L1 (PD-L1 expression \geq 5%) have a higher objective response rate.

Shuwen Biotech's PD-L1 kits and testing services have been used by leading pharmaceutical companies for dozens of clinical trials against PD-1 immunotherapeutics, contributing to the development of tumor immunotherapy drugs.

Shuwen Biotech's CAP-certified Shuwen Guanz Diagnostic Laboratories also successfully passed CAP's multi-site, multi-country proficiency testing for PD-L1 testing.